170 related articles for article (PubMed ID: 17049493)
1. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.
Khemawoot P; Yokogawa K; Shimada T; Miyamoto K
Biochem Pharmacol; 2007 Jan; 73(1):155-62. PubMed ID: 17049493
[TBL] [Abstract][Full Text] [Related]
2. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravenous chlorzoxazone in rats with dehydration and rehydration: effects of food intakes.
Kim YC; Kim YG; Kim EJ; Cho MK; Kim SG; Lee MG
Biopharm Drug Dispos; 2003 Mar; 24(2):53-61. PubMed ID: 12619050
[TBL] [Abstract][Full Text] [Related]
4. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent effects of Klebsiella pneumoniae endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, in rats: restoration of the parameters in 96 hour in KPLPS rats to control levels.
Jung HY; Kang HE; Choi YH; Kim SH; Lee MG
Biopharm Drug Dispos; 2009 Nov; 30(8):485-93. PubMed ID: 19753555
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucose supplementation on the pharmacokinetics of intravenous chlorzoxazone in rats with water deprivation for 72 h.
Kim YC; Lee I; Kim SG; Ko SH; Lee MG; Kim SH
Life Sci; 2006 Nov; 79(23):2179-86. PubMed ID: 16914164
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus.
Ahn CY; Bae SK; Jung YS; Lee I; Kim YC; Lee MG; Shin WG
Drug Metab Dispos; 2008 Jul; 36(7):1233-41. PubMed ID: 18378564
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation.
Baek HW; Bae SK; Lee MG; Sohn YT
J Pharm Sci; 2006 Nov; 95(11):2452-62. PubMed ID: 16886191
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytochrome P4502E1 (CYP2E1) activity and hepatic and lymphocyte mRNA expression in patients with chronic hepatitis C.
Haufroid V; Ligocka D; Wallemacq P; Lison D; Horsmans Y
Toxicol Lett; 2005 Jan; 155(1):171-7. PubMed ID: 15585372
[TBL] [Abstract][Full Text] [Related]
10. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats.
Rockich K; Blouin R
Drug Metab Dispos; 1999 Sep; 27(9):1074-7. PubMed ID: 10460809
[TBL] [Abstract][Full Text] [Related]
11. Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein-calorie malnutrition.
Kim YG; Cho MK; Kwon JW; Kim SG; Chung SJ; Shim CK; Le Myung G
Biopharm Drug Dispos; 2002 Apr; 23(3):121-9. PubMed ID: 12173547
[TBL] [Abstract][Full Text] [Related]
12. [Changes of CYP2E1 activity in diabetic rat model].
Li L; Zhang Y
Yao Xue Xue Bao; 1998 Dec; 33(12):891-5. PubMed ID: 12016852
[TBL] [Abstract][Full Text] [Related]
13. Effects of normothermic hepatic ischemia-reperfusion injury on the in vivo, isolated perfused liver, and microsomal disposition of chlorzoxazone, a cytochrome P450 2E1 probe, in rats.
Shaik IH; Mehvar R
J Pharm Sci; 2011 Dec; 100(12):5281-92. PubMed ID: 21780121
[TBL] [Abstract][Full Text] [Related]
14. In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene.
Piccoli P; Carrieri M; Padovano L; Di Mare M; Bartolucci GB; Fracasso ME; Lepera JS; Manno M
Toxicol Lett; 2010 Jan; 192(1):29-33. PubMed ID: 19900514
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.
Eap CB; Schnyder C; Besson J; Savary L; Buclin T
Clin Pharmacol Ther; 1998 Jul; 64(1):52-7. PubMed ID: 9695719
[TBL] [Abstract][Full Text] [Related]
16. Chlorzoxazone: a probe drug the metabolism of which can be used to monitor one-point blood sampling in the carbon tetrachloride-intoxicated rat.
Tanaka E
Hum Exp Toxicol; 2001 Aug; 20(8):381-5. PubMed ID: 11727787
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats.
Enriquez A; Leclercq I; Farrell GC; Robertson G
Biochem Biophys Res Commun; 1999 Feb; 255(2):300-6. PubMed ID: 10049703
[TBL] [Abstract][Full Text] [Related]
19. Chlorzoxazone metabolism by winter flounder liver microsomes: evidence for existence of a CYP2E1-like isoform in teleosts.
Wall KL; Crivello J
Toxicol Appl Pharmacol; 1998 Jul; 151(1):98-104. PubMed ID: 9705891
[TBL] [Abstract][Full Text] [Related]
20. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans.
Mishin VM; Rosman AS; Basu P; Kessova I; Oneta CM; Lieber CS
Am J Gastroenterol; 1998 Nov; 93(11):2154-61. PubMed ID: 9820389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
